Biocon Biologics appoints Shreehas Tambe as Managing Director and CEO
He will lead Biocon Biologics in realising its goal of being a global biosimilars leader
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
Biocon Biologics completely acquires Viatris’s global biosimilars business
Biocon Biologics will recognise the combined revenue and associated profits from the acquired collaboration biosimilars with…
Biocon Biologics outlicenses two biosimilar assets to Yoshindo for commercialisation in Japan
bUstekinumab and bDenosumab to address market opportunity of approximately $700 million
Biocon Sdn Bhd enters Malaysia Book of Records
The 562,000 sq ft facility has been recognised as the first and largest integrated insulin manufacturer in Malaysia by MBR
India’s medicine watchdog under the scanner once again
Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report
Biocon Biologics denies bribery allegations
A statement from the company claimed that besides its employees, all its consultants, suppliers and partners are also bound by a…
Biocon Biologics and Viatris launch Abevmy in Canada
Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…
CCI approves Serum Institute Life Sciences-Biocon Biologics deal
Once the deal is complete, Serum Institute Life Sciences will have about 15 per cent stake in Biocon Biologics, according to the…
Biocon Q4FY22 revenue at Rs 2,476 crores, up 21 per cent
FY22 revenue at Rs 8,397 crores, up 14 per cent; core EBITDA up 18 per cent at Rs 2,669 crores; PBT (before Exceptional Item) at…